Search tips
Search criteria 


Logo of moiMediators of Inflammation
Mediators Inflamm. 2000; 9(5): 223–228.
PMCID: PMC1781768

Effect of ricinoleic acid in acute and subchronic experimental models of inflammation.


Observational studies indicate that topical application of ricinoleic acid (RA), the main component of castor oil, exerts remarkable analgesic and anti-inflammatory effects. Pharmacological characterization has shown similarities between the effects of RA and those of capsaicin, suggesting a potential interaction of this drug on sensory neuropeptide-mediated neurogenic inflammation. The aim of this study was to assess RA anti-inflammatory activities in comparison with capsaicin in several models of acute and subchronic inflammation. The acute inflammation was induced by intradermal injection of carrageenan in the mouse or by histamine in the guinea-pig eyelid. In either experiment, the extent of the oedema thickness was measured. Subchronic oedema was induced by complete Freund's adjuvant injection in the ventral right paw of mice. Tissue substance P (SP) was measured in the carrageenan experiments by radioimmunoassay (RIA). It was found that the acute topical application of RA (0.9 mg/mouse) or capsaicin (0.09 mg/mouse) significantly increased the mouse paw oedema induced by carrageenan, while an 8-day repeated topical treatment with the same doses of both compounds resulted in a marked inhibition of carrageenan-induced paw oedema matched by a reduction in SP tissue levels. Similar effects were found against histamine-induced eyelid oedema in guinea-pigs after acute or repeated application of RA or capsaicin. RA and capsaicin given for 1-3 weeks reduced the established oedema induced by Freund's adjuvant, a subchronic model of inflammation, particularly if given by the intradermal route. Either in mouse paw or in guinea-pig eyelid, capsaicin but not RA by itself produced a slight hyperemia and activation of a behavioural response (e.g. scratching of the eyelids). On the basis of the present results, RA may be seen as a new capsaicin-like, non-pungent anti-inflammatory agent suitable for peripheral application.

Full Text

The Full Text of this article is available as a PDF (151K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Stewart JJ, Gaginella TS, Olsen WA, Bass P. Inhibitory actions of laxatives on motility and water and electrolyte transport in the gastrointestinal tract. J Pharmacol Exp Ther. 1975 Feb;192(2):458–467. [PubMed]
  • Dray A. Neuropharmacological mechanisms of capsaicin and related substances. Biochem Pharmacol. 1992 Aug 18;44(4):611–615. [PubMed]
  • Szallasi A. The vanilloid (capsaicin) receptor: receptor types and species differences. Gen Pharmacol. 1994 Mar;25(2):223–243. [PubMed]
  • Szallasi A, Bíró T, Szabó T, Modarres S, Petersen M, Klusch A, Blumberg PM, Krause JE, Sterner O. A non-pungent triprenyl phenol of fungal origin, scutigeral, stimulates rat dorsal root ganglion neurons via interaction at vanilloid receptors. Br J Pharmacol. 1999 Mar;126(6):1351–1358. [PMC free article] [PubMed]
  • Klopman G, Li JY. Quantitative structure-agonist activity relationship of capsaicin analogues. J Comput Aided Mol Des. 1995 Jun;9(3):283–294. [PubMed]
  • Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 1997 Oct 23;389(6653):816–824. [PubMed]
  • Maggi CA, Meli A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen Pharmacol. 1988;19(1):1–43. [PubMed]
  • Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev. 1991 Jun;43(2):143–201. [PubMed]
  • Vieira C, Evangelista S, Cirillo R, Terracciano R, Lippi A, Maggi CA, Manzini S. Antinociceptive activity of ricinoleic acid, a capsaicin-like compound devoid of pungent properties. Eur J Pharmacol. 2000 Oct 27;407(1-2):109–116. [PubMed]
  • McMahon SB, Lewin G, Bloom SR. The consequences of long-term topical capsaicin application in the rat. Pain. 1991 Mar;44(3):301–310. [PubMed]
  • Lippi A, Santicioli P, Criscuoli M, Maggi CA. Depolarization evoked co-release of tachykinins from enteric nerves in the guinea-pig proximal colon. Naunyn Schmiedebergs Arch Pharmacol. 1998 Mar;357(3):245–251. [PubMed]
  • Jancsó N, Jancsó-Gábor A, Szolcsányi J. The role of sensory nerve endings in neurogenic inflammation induced in human skin and in the eye and paw of the rat. Br J Pharmacol Chemother. 1968 May;33(1):32–41. [PubMed]
  • Lundblad L, Saria A, Lundberg JM, Anggård A. Increased vascular permeability in rat nasal mucosa induced by substance P and stimulation of capsaicin-sensitive trigeminal neurons. Acta Otolaryngol. 1983 Nov-Dec;96(5-6):479–484. [PubMed]
  • Saria A, Lundberg JM, Skofitsch G, Lembeck F. Vascular protein linkage in various tissue induced by substance P, capsaicin, bradykinin, serotonin, histamine and by antigen challenge. Naunyn Schmiedebergs Arch Pharmacol. 1983 Nov;324(3):212–218. [PubMed]
  • Cao YQ, Mantyh PW, Carlson EJ, Gillespie AM, Epstein CJ, Basbaum AI. Primary afferent tachykinins are required to experience moderate to intense pain. Nature. 1998 Mar 26;392(6674):390–394. [PubMed]
  • Birch PJ, Harrison SM, Hayes AG, Rogers H, Tyers MB. The non-peptide NK1 receptor antagonist, (+/-)-CP-96,345, produces antinociceptive and anti-oedema effects in the rat. Br J Pharmacol. 1992 Mar;105(3):508–510. [PMC free article] [PubMed]
  • Cao T, Pintér E, Al-Rashed S, Gerard N, Hoult JR, Brain SD. Neurokinin-1 receptor agonists are involved in mediating neutrophil accumulation in the inflamed, but not normal, cutaneous microvasculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol. 2000 May 15;164(10):5424–5429. [PubMed]
  • Jancsó N, Jancsó-Gábor A, Szolcsányi J. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother. 1967 Sep;31(1):138–151. [PubMed]
  • Jessell TM, Iversen LL, Cuello AC. Capsaicin-induced depletion of substance P from primary sensory neurones. Brain Res. 1978 Aug 18;152(1):183–188. [PubMed]
  • Gamse R, Holzer P, Lembeck F. Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin. Br J Pharmacol. 1980 Feb;68(2):207–213. [PMC free article] [PubMed]
  • Crimi N, Polosa R, Maccarrone C, Palermo B, Palermo F, Mistretta A. Effect of topical application with capsaicin on skin responses to bradykinin and histamine in man. Clin Exp Allergy. 1992 Oct;22(10):933–939. [PubMed]
  • Saria A, Martling CR, Yan Z, Theodorsson-Norheim E, Gamse R, Lundberg JM. Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am Rev Respir Dis. 1988 Jun;137(6):1330–1335. [PubMed]
  • Amann R, Schuligoi R, Lanz I, Donnerer J. Histamine-induced edema in the rat paw--effect of capsaicin denervation and a CGRP receptor antagonist. Eur J Pharmacol. 1995 Jun 12;279(2-3):227–231. [PubMed]
  • Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience. 1992 Aug;49(3):693–698. [PubMed]
  • Colpaert FC, Donnerer J, Lembeck F. Effects of capsaicin on inflammation and on the substance P content of nervous tissues in rats with adjuvant arthritis. Life Sci. 1983 Apr 18;32(16):1827–1834. [PubMed]
  • Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH., Jr Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. J Am Acad Dermatol. 1986 Sep;15(3):504–507. [PubMed]
  • Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989 Aug;21(2 Pt 1):265–270. [PubMed]
  • Watson CP, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain. 1992 Dec;51(3):375–379. [PubMed]

Articles from Mediators of Inflammation are provided here courtesy of Hindawi